Share Price and Basic Stock Data
Last Updated: February 13, 2026, 9:55 pm
| PEG Ratio | -3.42 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Auro Laboratories Ltd operates within the pharmaceuticals sector, showcasing a market capitalization of ₹187 Cr and a current share price of ₹300. The company reported sales of ₹52.89 Cr for the fiscal year ending March 2023, slightly up from ₹50.87 Cr in the previous year. However, in the trailing twelve months (TTM), revenue stood at ₹22.06 Cr, indicating a significant decline from prior periods. Quarterly sales trends reveal fluctuations, with the highest sales recorded at ₹17.98 Cr in December 2023 and a low of ₹5.72 Cr in June 2024. This inconsistency may reflect challenges in market conditions or operational efficiency. The operating profit margin (OPM) has varied, peaking at 26.58% in September 2025, illustrating potential efficiency gains in recent quarters. Overall, while Auro Laboratories has shown capacity for revenue generation, it faces challenges in maintaining consistent sales growth, a critical factor for long-term sustainability in the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Profitability metrics for Auro Laboratories indicate a mixed performance. The return on equity (ROE) stood at 4.33%, while return on capital employed (ROCE) was reported at 3.85%. These figures suggest that the company is generating a modest return on shareholders’ investments, falling below typical sector ranges, which often exceed 10%. The net profit for the fiscal year ending March 2023 was ₹2.44 Cr, with a net profit margin of 4.61%, reflecting pressure on profitability. Additionally, the interest coverage ratio (ICR) was 3.75x, indicating that the company’s earnings comfortably cover its interest obligations. However, the cash conversion cycle (CCC) measured at 76.01 days suggests inefficiencies in managing working capital, particularly in inventory and receivables management. Auro Laboratories must address these efficiency issues to enhance overall profitability and align with industry benchmarks.
Balance Sheet Strength and Financial Ratios
Auro Laboratories’ balance sheet presents a mixed picture of financial stability. As of March 2025, total borrowings amounted to ₹43.94 Cr against reserves of ₹37.35 Cr, indicating a reliance on debt financing. The total liabilities stood at ₹99.09 Cr, reflecting an increase from previous years, while total assets also rose to ₹99.09 Cr. The debt-to-equity ratio of 0.99x suggests a heightened financial risk, considering typical sector averages generally range lower. The book value per share improved to ₹68.94, indicating a strengthening of equity base despite rising liabilities. Furthermore, the current ratio stood at 0.99, slightly below the ideal benchmark of 1, suggesting potential liquidity risks. The company’s ability to manage its debt levels and improve liquidity will be crucial for future operational flexibility and financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Auro Laboratories reveals a stable promoter holding of 52.17%, indicating strong management control over the company. The public shareholding accounted for 47.82%, while institutional investments from Domestic Institutional Investors (DIIs) were negligible at 0.01%. This limited institutional interest may reflect cautious sentiment among larger investors regarding the company’s growth prospects. Over the past year, the number of shareholders has declined from 11,135 to 8,860, indicating a potential decrease in investor confidence or liquidity issues. The low participation from Foreign Institutional Investors (FIIs) further underscores the cautious outlook. It is essential for Auro Laboratories to engage with investors and improve transparency to bolster shareholder confidence and potentially attract institutional investments, which can provide stability and support for future growth initiatives.
Outlook, Risks, and Final Insight
Looking ahead, Auro Laboratories faces several strengths and risks that will shape its future trajectory. On the positive side, the company has demonstrated resilience in its operating profit margins, particularly with the recent peak of 26.58%. Additionally, the stable promoter holding suggests committed management. Conversely, significant risks include financial leverage with a high debt-to-equity ratio and fluctuating sales figures, which may hinder consistent growth. Moreover, the low ROE and ROCE raise concerns about efficient capital utilization. Stakeholders should monitor the company’s efforts to enhance operational efficiency and manage debt levels. In scenarios where Auro Laboratories can stabilize its revenue streams and improve efficiency metrics, it may position itself favorably in the competitive landscape. However, failure to address these challenges could result in continued volatility in performance and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 143/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,391 Cr. | 312 | 479/192 | 71.0 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 201 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,957.38 Cr | 1,098.00 | 53.12 | 201.93 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.56 | 15.62 | 13.52 | 10.18 | 13.41 | 17.98 | 12.06 | 5.72 | 3.10 | 3.05 | 7.40 | 2.77 | 8.84 |
| Expenses | 11.54 | 15.17 | 11.17 | 9.02 | 10.38 | 13.90 | 9.65 | 4.39 | 2.38 | 2.60 | 6.59 | 2.74 | 6.49 |
| Operating Profit | 1.02 | 0.45 | 2.35 | 1.16 | 3.03 | 4.08 | 2.41 | 1.33 | 0.72 | 0.45 | 0.81 | 0.03 | 2.35 |
| OPM % | 8.12% | 2.88% | 17.38% | 11.39% | 22.60% | 22.69% | 19.98% | 23.25% | 23.23% | 14.75% | 10.95% | 1.08% | 26.58% |
| Other Income | -0.16 | 0.43 | 0.62 | 0.36 | 0.32 | 0.42 | 0.40 | 0.20 | 0.31 | 0.14 | 0.13 | 0.42 | 0.98 |
| Interest | 0.32 | 0.10 | 0.13 | 0.27 | 0.35 | 0.44 | -0.32 | 0.25 | 0.28 | 0.25 | 0.30 | 0.28 | 0.96 |
| Depreciation | 0.25 | 0.27 | 0.30 | 0.27 | 0.27 | 0.27 | 0.28 | 0.27 | 0.27 | 0.27 | 0.29 | 0.27 | 0.65 |
| Profit before tax | 0.29 | 0.51 | 2.54 | 0.98 | 2.73 | 3.79 | 2.85 | 1.01 | 0.48 | 0.07 | 0.35 | -0.10 | 1.72 |
| Tax % | 27.59% | 27.45% | 29.53% | 27.55% | 27.84% | 27.70% | 18.60% | 24.75% | 25.00% | 28.57% | -11.43% | 0.00% | 58.14% |
| Net Profit | 0.21 | 0.37 | 1.78 | 0.71 | 1.97 | 2.73 | 2.32 | 0.75 | 0.36 | 0.05 | 0.39 | -0.11 | 0.72 |
| EPS in Rs | 0.34 | 0.59 | 2.86 | 1.14 | 3.16 | 4.38 | 3.72 | 1.20 | 0.58 | 0.08 | 0.63 | -0.18 | 1.16 |
Last Updated: December 27, 2025, 11:46 pm
Below is a detailed analysis of the quarterly data for Auro Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 8.84 Cr.. The value appears strong and on an upward trend. It has increased from 2.77 Cr. (Jun 2025) to 8.84 Cr., marking an increase of 6.07 Cr..
- For Expenses, as of Sep 2025, the value is 6.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.74 Cr. (Jun 2025) to 6.49 Cr., marking an increase of 3.75 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.35 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Jun 2025) to 2.35 Cr., marking an increase of 2.32 Cr..
- For OPM %, as of Sep 2025, the value is 26.58%. The value appears strong and on an upward trend. It has increased from 1.08% (Jun 2025) to 26.58%, marking an increase of 25.50%.
- For Other Income, as of Sep 2025, the value is 0.98 Cr.. The value appears strong and on an upward trend. It has increased from 0.42 Cr. (Jun 2025) to 0.98 Cr., marking an increase of 0.56 Cr..
- For Interest, as of Sep 2025, the value is 0.96 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.28 Cr. (Jun 2025) to 0.96 Cr., marking an increase of 0.68 Cr..
- For Depreciation, as of Sep 2025, the value is 0.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.27 Cr. (Jun 2025) to 0.65 Cr., marking an increase of 0.38 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.72 Cr.. The value appears strong and on an upward trend. It has increased from -0.10 Cr. (Jun 2025) to 1.72 Cr., marking an increase of 1.82 Cr..
- For Tax %, as of Sep 2025, the value is 58.14%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Jun 2025) to 58.14%, marking an increase of 58.14%.
- For Net Profit, as of Sep 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from -0.11 Cr. (Jun 2025) to 0.72 Cr., marking an increase of 0.83 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.16. The value appears strong and on an upward trend. It has increased from -0.18 (Jun 2025) to 1.16, marking an increase of 1.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.74 | 32.65 | 27.91 | 35.47 | 40.79 | 46.82 | 43.79 | 54.25 | 50.87 | 52.89 | 53.64 | 19.40 | 22.06 |
| Expenses | 30.95 | 29.71 | 25.11 | 31.03 | 34.43 | 39.83 | 37.51 | 43.01 | 46.24 | 48.50 | 42.96 | 16.00 | 18.42 |
| Operating Profit | 2.79 | 2.94 | 2.80 | 4.44 | 6.36 | 6.99 | 6.28 | 11.24 | 4.63 | 4.39 | 10.68 | 3.40 | 3.64 |
| OPM % | 8.27% | 9.00% | 10.03% | 12.52% | 15.59% | 14.93% | 14.34% | 20.72% | 9.10% | 8.30% | 19.91% | 17.53% | 16.50% |
| Other Income | 0.06 | 0.24 | 0.42 | 0.53 | 0.51 | 0.96 | 0.97 | 0.76 | 1.09 | 0.94 | 1.50 | 0.66 | 1.67 |
| Interest | 1.53 | 1.66 | 1.66 | 1.18 | 1.21 | 0.87 | 0.58 | 0.46 | 0.83 | 0.81 | 0.74 | 1.08 | 1.79 |
| Depreciation | 0.74 | 0.72 | 0.68 | 0.86 | 0.93 | 1.01 | 1.02 | 1.04 | 1.02 | 1.07 | 1.09 | 1.10 | 1.48 |
| Profit before tax | 0.58 | 0.80 | 0.88 | 2.93 | 4.73 | 6.07 | 5.65 | 10.50 | 3.87 | 3.45 | 10.35 | 1.88 | 2.04 |
| Tax % | 0.00% | 0.00% | 0.00% | 72.01% | 25.16% | 27.51% | 27.96% | 31.62% | 26.61% | 28.99% | 24.64% | 2.13% | |
| Net Profit | 0.58 | 0.80 | 0.88 | 0.82 | 3.53 | 4.40 | 4.05 | 7.18 | 2.84 | 2.44 | 7.79 | 1.84 | 1.05 |
| EPS in Rs | 0.93 | 1.28 | 1.41 | 1.32 | 5.66 | 7.06 | 6.50 | 11.52 | 4.56 | 3.91 | 12.50 | 2.95 | 1.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.93% | 10.00% | -6.82% | 330.49% | 24.65% | -7.95% | 77.28% | -60.45% | -14.08% | 219.26% | -76.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | -27.93% | -16.82% | 337.31% | -305.84% | -32.60% | 85.24% | -137.73% | 46.36% | 233.35% | -295.64% |
Auro Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -15% |
| 3 Years: | -27% |
| TTM: | -67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -15% |
| 3 Years: | -13% |
| TTM: | -91% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 33% |
| 3 Years: | 42% |
| 1 Year: | 23% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 2:31 pm
Balance Sheet
Last Updated: December 10, 2025, 3:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 | 6.23 |
| Reserves | 0.67 | 1.47 | 2.35 | 3.18 | 6.75 | 11.18 | 15.27 | 22.35 | 25.29 | 27.97 | 35.73 | 36.74 | 37.35 |
| Borrowings | 14.80 | 16.41 | 12.62 | 4.95 | 9.20 | 8.09 | 3.16 | 3.16 | 13.78 | 6.41 | 26.25 | 42.72 | 43.94 |
| Other Liabilities | 5.14 | 4.67 | 4.49 | 12.45 | 8.23 | 7.97 | 7.68 | 10.15 | 9.66 | 15.38 | 17.52 | 13.40 | 23.25 |
| Total Liabilities | 26.84 | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 99.09 | 110.77 |
| Fixed Assets | 10.51 | 9.80 | 9.13 | 13.00 | 13.02 | 14.59 | 14.24 | 13.56 | 13.61 | 12.62 | 22.15 | 21.06 | 76.84 |
| CWIP | 0.06 | 0.82 | 3.33 | 0.23 | 1.07 | 0.12 | 0.12 | 0.13 | 3.68 | 7.67 | 32.68 | 56.48 | 10.37 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Other Assets | 16.22 | 18.11 | 13.18 | 13.53 | 16.27 | 18.71 | 17.93 | 28.15 | 37.62 | 35.65 | 30.85 | 21.50 | 23.51 |
| Total Assets | 26.84 | 28.78 | 25.69 | 26.81 | 30.41 | 33.47 | 32.34 | 41.89 | 54.96 | 55.99 | 85.73 | 99.09 | 110.77 |
Below is a detailed analysis of the balance sheet data for Auro Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.23 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.23 Cr..
- For Reserves, as of Sep 2025, the value is 37.35 Cr.. The value appears strong and on an upward trend. It has increased from 36.74 Cr. (Mar 2025) to 37.35 Cr., marking an increase of 0.61 Cr..
- For Borrowings, as of Sep 2025, the value is 43.94 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 42.72 Cr. (Mar 2025) to 43.94 Cr., marking an increase of 1.22 Cr..
- For Other Liabilities, as of Sep 2025, the value is 23.25 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13.40 Cr. (Mar 2025) to 23.25 Cr., marking an increase of 9.85 Cr..
- For Total Liabilities, as of Sep 2025, the value is 110.77 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 99.09 Cr. (Mar 2025) to 110.77 Cr., marking an increase of 11.68 Cr..
- For Fixed Assets, as of Sep 2025, the value is 76.84 Cr.. The value appears strong and on an upward trend. It has increased from 21.06 Cr. (Mar 2025) to 76.84 Cr., marking an increase of 55.78 Cr..
- For CWIP, as of Sep 2025, the value is 10.37 Cr.. The value appears to be declining and may need further review. It has decreased from 56.48 Cr. (Mar 2025) to 10.37 Cr., marking a decrease of 46.11 Cr..
- For Investments, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05 Cr..
- For Other Assets, as of Sep 2025, the value is 23.51 Cr.. The value appears strong and on an upward trend. It has increased from 21.50 Cr. (Mar 2025) to 23.51 Cr., marking an increase of 2.01 Cr..
- For Total Assets, as of Sep 2025, the value is 110.77 Cr.. The value appears strong and on an upward trend. It has increased from 99.09 Cr. (Mar 2025) to 110.77 Cr., marking an increase of 11.68 Cr..
However, the Borrowings (43.94 Cr.) are higher than the Reserves (37.35 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -12.01 | -13.47 | -9.82 | -0.51 | -2.84 | -1.10 | 3.12 | 8.08 | -9.15 | -2.02 | -15.57 | -39.32 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46.95 | 94.80 | 66.04 | 79.13 | 74.90 | 66.26 | 48.18 | 49.12 | 97.65 | 85.57 | 91.11 | 176.67 |
| Inventory Days | 115.33 | 89.37 | 86.72 | 21.65 | 22.00 | 42.98 | 60.54 | 32.60 | 47.32 | 120.27 | 113.24 | 145.45 |
| Days Payable | 62.97 | 56.12 | 72.03 | 80.26 | 78.26 | 66.19 | 70.67 | 73.51 | 54.12 | 117.41 | 85.34 | 246.11 |
| Cash Conversion Cycle | 99.30 | 128.05 | 80.73 | 20.52 | 18.64 | 43.05 | 38.04 | 8.20 | 90.86 | 88.44 | 119.01 | 76.01 |
| Working Capital Days | 19.15 | 39.13 | 26.68 | 67.20 | 64.70 | 63.46 | 51.09 | 29.40 | 36.59 | 104.28 | 35.86 | -14.30 |
| ROCE % | 9.43% | 10.74% | 11.21% | 23.06% | 32.51% | 29.11% | 24.84% | 38.87% | 12.20% | 9.92% | 20.38% | 3.85% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| Diluted EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| Cash EPS (Rs.) | 4.71 | 14.26 | 5.64 | 6.20 | 13.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.94 | 67.32 | 54.87 | 50.58 | 45.86 |
| Revenue From Operations / Share (Rs.) | 31.12 | 86.06 | 84.87 | 81.61 | 87.05 |
| PBDIT / Share (Rs.) | 6.51 | 19.53 | 8.56 | 9.17 | 19.25 |
| PBIT / Share (Rs.) | 4.75 | 17.78 | 6.83 | 7.54 | 17.59 |
| PBT / Share (Rs.) | 3.02 | 16.60 | 5.53 | 6.21 | 16.86 |
| Net Profit / Share (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 |
| PBDIT Margin (%) | 20.92 | 22.69 | 10.08 | 11.24 | 22.11 |
| PBIT Margin (%) | 15.27 | 20.66 | 8.05 | 9.24 | 20.20 |
| PBT Margin (%) | 9.69 | 19.28 | 6.51 | 7.61 | 19.36 |
| Net Profit Margin (%) | 9.47 | 14.52 | 4.61 | 5.59 | 13.23 |
| Return on Networth / Equity (%) | 4.27 | 18.57 | 7.14 | 9.02 | 25.11 |
| Return on Capital Employeed (%) | 3.82 | 17.93 | 11.25 | 13.49 | 32.80 |
| Return On Assets (%) | 1.85 | 9.08 | 4.36 | 5.17 | 17.13 |
| Long Term Debt / Equity (X) | 0.71 | 0.43 | 0.05 | 0.02 | 0.07 |
| Total Debt / Equity (X) | 0.99 | 0.62 | 0.18 | 0.02 | 0.07 |
| Asset Turnover Ratio (%) | 0.20 | 0.75 | 0.95 | 1.05 | 1.46 |
| Current Ratio (X) | 0.99 | 1.29 | 1.97 | 1.87 | 3.32 |
| Quick Ratio (X) | 0.82 | 0.94 | 1.32 | 1.66 | 3.02 |
| Inventory Turnover Ratio (X) | 3.26 | 2.90 | 4.66 | 9.92 | 8.30 |
| Interest Coverage Ratio (X) | 3.75 | 16.55 | 6.55 | 6.92 | 26.18 |
| Interest Coverage Ratio (Post Tax) (X) | 2.70 | 11.59 | 4.00 | 4.44 | 16.66 |
| Enterprise Value (Cr.) | 185.78 | 125.03 | 37.80 | 50.97 | 38.05 |
| EV / Net Operating Revenue (X) | 9.58 | 2.33 | 0.71 | 1.00 | 0.70 |
| EV / EBITDA (X) | 45.76 | 10.27 | 7.09 | 8.91 | 3.17 |
| MarketCap / Net Operating Revenue (X) | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| Price / BV (X) | 3.34 | 2.39 | 0.99 | 1.98 | 1.77 |
| Price / Net Operating Revenue (X) | 7.41 | 1.87 | 0.64 | 1.23 | 0.93 |
| EarningsYield | 0.01 | 0.07 | 0.07 | 0.04 | 0.14 |
After reviewing the key financial ratios for Auro Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 5. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.71. This value is within the healthy range. It has decreased from 14.26 (Mar 24) to 4.71, marking a decrease of 9.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.94. It has increased from 67.32 (Mar 24) to 68.94, marking an increase of 1.62.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.94. It has increased from 67.32 (Mar 24) to 68.94, marking an increase of 1.62.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 31.12. It has decreased from 86.06 (Mar 24) to 31.12, marking a decrease of 54.94.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 6.51. This value is within the healthy range. It has decreased from 19.53 (Mar 24) to 6.51, marking a decrease of 13.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.75. This value is within the healthy range. It has decreased from 17.78 (Mar 24) to 4.75, marking a decrease of 13.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has decreased from 16.60 (Mar 24) to 3.02, marking a decrease of 13.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.95. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 2.95, marking a decrease of 9.55.
- For PBDIT Margin (%), as of Mar 25, the value is 20.92. This value is within the healthy range. It has decreased from 22.69 (Mar 24) to 20.92, marking a decrease of 1.77.
- For PBIT Margin (%), as of Mar 25, the value is 15.27. This value is within the healthy range. It has decreased from 20.66 (Mar 24) to 15.27, marking a decrease of 5.39.
- For PBT Margin (%), as of Mar 25, the value is 9.69. This value is below the healthy minimum of 10. It has decreased from 19.28 (Mar 24) to 9.69, marking a decrease of 9.59.
- For Net Profit Margin (%), as of Mar 25, the value is 9.47. This value is within the healthy range. It has decreased from 14.52 (Mar 24) to 9.47, marking a decrease of 5.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 15. It has decreased from 18.57 (Mar 24) to 4.27, marking a decrease of 14.30.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 10. It has decreased from 17.93 (Mar 24) to 3.82, marking a decrease of 14.11.
- For Return On Assets (%), as of Mar 25, the value is 1.85. This value is below the healthy minimum of 5. It has decreased from 9.08 (Mar 24) to 1.85, marking a decrease of 7.23.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 0.71, marking an increase of 0.28.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.99. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 0.99, marking an increase of 0.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.20. It has decreased from 0.75 (Mar 24) to 0.20, marking a decrease of 0.55.
- For Current Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1.5. It has decreased from 1.29 (Mar 24) to 0.99, marking a decrease of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.82, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.26. This value is below the healthy minimum of 4. It has increased from 2.90 (Mar 24) to 3.26, marking an increase of 0.36.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.75. This value is within the healthy range. It has decreased from 16.55 (Mar 24) to 3.75, marking a decrease of 12.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.70. This value is below the healthy minimum of 3. It has decreased from 11.59 (Mar 24) to 2.70, marking a decrease of 8.89.
- For Enterprise Value (Cr.), as of Mar 25, the value is 185.78. It has increased from 125.03 (Mar 24) to 185.78, marking an increase of 60.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.58. This value exceeds the healthy maximum of 3. It has increased from 2.33 (Mar 24) to 9.58, marking an increase of 7.25.
- For EV / EBITDA (X), as of Mar 25, the value is 45.76. This value exceeds the healthy maximum of 15. It has increased from 10.27 (Mar 24) to 45.76, marking an increase of 35.49.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.41. This value exceeds the healthy maximum of 3. It has increased from 1.87 (Mar 24) to 7.41, marking an increase of 5.54.
- For Price / BV (X), as of Mar 25, the value is 3.34. This value exceeds the healthy maximum of 3. It has increased from 2.39 (Mar 24) to 3.34, marking an increase of 0.95.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.41. This value exceeds the healthy maximum of 3. It has increased from 1.87 (Mar 24) to 7.41, marking an increase of 5.54.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.01, marking a decrease of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Auro Laboratories Ltd:
- Net Profit Margin: 9.47%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.82% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.27% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 61.6 (Industry average Stock P/E: 53.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.99
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.47%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | K-56, M.I.D.C. Industrial Area, Palghar District Maharashtra 401506 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sharat Deorah | Chairman & Managing Director |
| Mr. Kiran Suresh Kulkarni | Whole Time Director |
| Mr. Siddhartha Deorah | Whole Time Director |
| Mr. Mahendra Kumar Daga | Ind. Non-Executive Director |
| Mrs. Kavita Vijayakant Sharma | Ind. Non-Executive Director |
| Mr. Vishal Kailashchandra Jhunjhunwala | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Auro Laboratories Ltd?
Auro Laboratories Ltd's intrinsic value (as of 14 February 2026) is ₹124.75 which is 57.28% lower the current market price of ₹292.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹182 Cr. market cap, FY2025-2026 high/low of ₹309/159, reserves of ₹37.35 Cr, and liabilities of ₹110.77 Cr.
What is the Market Cap of Auro Laboratories Ltd?
The Market Cap of Auro Laboratories Ltd is 182 Cr..
What is the current Stock Price of Auro Laboratories Ltd as on 14 February 2026?
The current stock price of Auro Laboratories Ltd as on 14 February 2026 is ₹292.
What is the High / Low of Auro Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Auro Laboratories Ltd stocks is ₹309/159.
What is the Stock P/E of Auro Laboratories Ltd?
The Stock P/E of Auro Laboratories Ltd is 61.6.
What is the Book Value of Auro Laboratories Ltd?
The Book Value of Auro Laboratories Ltd is 69.9.
What is the Dividend Yield of Auro Laboratories Ltd?
The Dividend Yield of Auro Laboratories Ltd is 0.00 %.
What is the ROCE of Auro Laboratories Ltd?
The ROCE of Auro Laboratories Ltd is 3.85 %.
What is the ROE of Auro Laboratories Ltd?
The ROE of Auro Laboratories Ltd is 4.33 %.
What is the Face Value of Auro Laboratories Ltd?
The Face Value of Auro Laboratories Ltd is 10.0.